Stuttgart
17.09.26 | 16:50
0,147 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,143 | 0,153 | 17:07 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.09. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 385 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 26.08. | Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer | 482 | Business Wire | Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients Original research conducted and funded by Korea's National Evidence-Based Healthcare... ► Artikel lesen | |
| 07.08. | Mauna Kea Technologies: Monthly information regarding the total number of voting rights and shares comprising the share capital | 537 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 28.07. | Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio and Its Combination with AI for the Diagnosis of Pancreatic Cysts | 500 | Business Wire | International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio AI Cellvizio increases accuracy... ► Artikel lesen | |
| 21.07. | Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth | 464 | Business Wire | H1 2026 sales reached €3,203K, up +44% at constant exchange rates (CER) and +39% as reported1 CellTolerance sales increased +145% to €0.9 million, driven by strong international expansion Strong... ► Artikel lesen | |
| 16.07. | Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity | 411 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces... ► Artikel lesen | |
| 16.07. | Mauna Kea Technologies Secures €4 Million Optional Shareholder Loan To Support Commercial Expansion | 2 | pulse2.com | ||
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 15.07. | Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth | 696 | Business Wire | Shareholder loan agreement with long-term financial partner Vester Finance provides Mauna Kea with the contractual option to draw funds, with no obligation to do so, over the next 24 months Financing... ► Artikel lesen | |
| 06.07. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 323 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 04.06. | Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026 | 474 | Business Wire | All resolutions recommended by the Board of Directors were adopted, with the exception of the 15th
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio,... ► Artikel lesen | |
| 03.06. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 416 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.06. | Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying "Triple Healing", a Cellvizio- Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis | 346 | Business Wire | 100% of patients achieving Cellvizio-assessed triple healing remained relapse-free over 24 months (0 of 29), versus a ~33% relapse rate among those who did not A decade of converging, multi-center... ► Artikel lesen | |
| 20.05. | Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance Commercial Installation | 455 | Business Wire | IBS-related symptom prevalence in the region is among the highest in the world, reaching an average of 27% An ideal region uniquely positioned for CellTolerance's direct out-of-pocket commercial... ► Artikel lesen | |
| 18.05. | Mauna Kea Technologies Announces Nomination of 3 New Directors | 617 | Business Wire | Their recognized expertise will help accelerate the strategic transformation launched in 2025 Subject to approval at upcoming Annual General Meeting
Regulatory News:
Mauna Kea Technologies... ► Artikel lesen | |
| 04.05. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 377 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 30.04. | Mauna Kea Technologies: Publication of the 2025 Annual Financial Report | 1.010 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 28.04. | Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio To Be Presented at Digestive Disease Week 2026 | 784 | Business Wire | 10 Cellvizio-related abstracts, including landmark multicenter pancreatic cyst data, AI-driven IBD assessment, and new food intolerance applications, reinforce the breadth and depth of real-time... ► Artikel lesen | |
| 22.04. | Mauna Kea Technologies meldet starkes Wachstum im ersten Quartal 2026 | 1 | Investing.com Deutsch | ||
| 22.04. | Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025 | 878 | Business Wire | Fundamental balance sheet reset achieved through a 70% reduction in financial debt and €20M increase in equity Product sales momentum in 2025 driven by record U.S. sales performance (+38% CER)... ► Artikel lesen | |
| 15.04. | Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth | 477 | Business Wire | Q1 2026 sales reached €1,527K (excluding licensing), an increase of +68% at Constant Exchange Rate CER) and +57% as reported U.S. sales grew +34% CER (+21% reported) and +51% on an invoiced basis... ► Artikel lesen |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,068 | +5,56 % | Dr. Steven S. Sangha: Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc. | Toronto, Ontario--(Newsfile Corp. - September 11, 2026) - Steven Sangha announces he has entered into a voting and support agreement ("Voting Agreement") with Seraxis Holdings, Inc. ("Seraxis") in connection... ► Artikel lesen | |
| FAMICORD | 2,890 | -2,03 % | Vita 34 erweitert die Stammzellvorsorge: Jetzt auch Plazentagewebe für die Zukunft sichern | Leipzig (ots) - Neben Nabelschnurblut und Nabelschnurgewebe kann ab sofort auch die Plazenta als wertvolle Stammzellquelle eingelagert werdenDie Geburt eines Kindes ist ein einzigartiger Moment. Sie... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,490 | +0,81 % | Geratherm Medical Aktie: Der Umbau soll die Wende bringen | Geratherm Medical steckt operativ weiter in einer schwierigen Phase. Im ersten Halbjahr 2026 sank der Umsatz um 12,5 Prozent auf 7,0 Millionen Euro, während das EBIT auf minus 0,5 Millionen Euro zurückging.... ► Artikel lesen | |
| CERENOME | 1,756 | -0,34 % | Cerenome, Inc.: Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division | HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announces the appointment of Samantha... ► Artikel lesen | |
| MEDICLIN | 5,750 | +1,77 % | Mediclin: Indirekter Profiteur | Sondersituationen wie Übernahmen, Turnarounds oder Abfindungsspekulationen sind gerade in der Spezialwerteszene eine beliebte Anlagestrategie. So rückte im Herbst 2025 etwa der auf den Reha-Bereich... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,140 | +1,90 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| VERU | 2,385 | +2,80 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| LIFEWARD | 6,910 | 0,00 % | Lifeward legt Termin für jährliche und außerordentliche Hauptversammlung 2026 fest | ||
| LIGHT AI | 0,100 | -2,44 % | XFRA 0HC: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| IMUNON | 1,230 | -1,60 % | Imunon, Inc.: IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 | ||
| FRESENIUS MEDICAL CARE | 39,070 | -2,40 % | EQS-PVR: Fresenius Medical Care AG: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG | EQS Stimmrechtsmitteilung: Fresenius Medical Care AG
Fresenius Medical Care AG: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG
10.09.2026... ► Artikel lesen | |
| AETHLON MEDICAL | 7,380 | +416,08 % | Morning Market Movers: Aethlon Medical, CID HoldCo, Longeveron, Delixy See Big Swings | OTTAWA (dpa-AFX) - At 8:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| FRESENIUS | 45,900 | -0,52 % | EQS-DD: Fresenius SE & Co. KGaA: Sara Hennicken, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
10.09.2026 / 11:59... ► Artikel lesen |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,147 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.